Equillium Announces Preclinical Data From New Orally Deliverable Multi-Cytokine Inhibitor In Presentation At The 18th Annual Peptide Therapeutics Symposium
Portfolio Pulse from Benzinga Newsdesk
Equillium Inc. (NASDAQ:EQ) presented preclinical data on EQ302, a second generation orally deliverable multi-cytokine inhibitor, at the 18th Annual Peptide Therapeutics Symposium. EQ302 is designed to target IL-15 and IL-21 and is being developed for potential use in treating various gastrointestinal diseases. The data showed that EQ302, when administered orally to mice, inhibited IL-15-induced IFNγ transcription in the gastrointestinal tract, indicating potential utility for Celiac Disease and inflammatory bowel disease.
October 16, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Equillium's presentation of promising preclinical data on EQ302 could potentially boost investor confidence in the company's research and development capabilities and its pipeline of therapeutics.
The presentation of positive preclinical data on EQ302, a potential treatment for gastrointestinal diseases, could be seen as a positive development for Equillium. This could potentially lead to increased investor confidence in the company's research and development capabilities and its pipeline of therapeutics, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100